A citation-based method for searching scientific literature

Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel, Harald Stein, Dido Lenze, Martin-Leo Hansmann, Sylvia Hartmann, Peter Möller, Sergio Cogliatti, Georg Lenz, Lorenz Trümper, Markus Löffler, Norbert Schmitz, Michael Pfreundschuh, Andreas Rosenwald, German Ott. J Clin Oncol 2017
Times Cited: 127







List of co-cited articles
555 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
59

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
56

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
749
53

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Andreas Rosenwald, George Wright, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Randy D Gascoyne, H Konrad Muller-Hermelink, Erlend B Smeland, Jena M Giltnane,[...]. N Engl J Med 2002
43

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
42

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
636
40

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
649
40

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.
David W Scott, Anja Mottok, Daisuke Ennishi, George W Wright, Pedro Farinha, Susana Ben-Neriah, Robert Kridel, Garrett S Barry, Christoffer Hother, Pau Abrisqueta,[...]. J Clin Oncol 2015
222
38

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
471
37

Stromal gene signatures in large-B-cell lymphomas.
G Lenz, G Wright, S S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal,[...]. N Engl J Med 2008
36


Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
498
32

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
David W Scott, George W Wright, P Mickey Williams, Chih-Jian Lih, William Walsh, Elaine S Jaffe, Andreas Rosenwald, Elias Campo, Wing C Chan, Joseph M Connors,[...]. Blood 2014
374
30


MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Heike Horn, Marita Ziepert, Claudia Becher, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Michael Hummel, Harald Stein, Martin-Leo Hansmann,[...]. Blood 2013
369
24

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Daisuke Ennishi, Aixiang Jiang, Merrill Boyle, Brett Collinge, Bruno M Grande, Susana Ben-Neriah, Christopher Rushton, Jeffrey Tang, Nicole Thomas, Graham W Slack,[...]. J Clin Oncol 2019
132
22

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Gonzalo Gutiérrez-García, Teresa Cardesa-Salzmann, Fina Climent, Eva González-Barca, Santiago Mercadal, José L Mate, Juan M Sancho, Leonor Arenillas, Sergi Serrano, Lourdes Escoda,[...]. Blood 2011
233
21

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Paul N Meyer, Kai Fu, Timothy C Greiner, Lynette M Smith, Jan Delabie, Randy D Gascoyne, German Ott, Andreas Rosenwald, Rita M Braziel, Elias Campo,[...]. J Clin Oncol 2011
339
20

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
Chulin Sha, Sharon Barrans, Francesco Cucco, Michael A Bentley, Matthew A Care, Thomas Cummin, Hannah Kennedy, Joe S Thompson, Rahman Uddin, Lisa Worrillow,[...]. J Clin Oncol 2019
93
21

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Laurie H Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J Savage, Tamara Shenkier, Judy Sutherland,[...]. Blood 2007
900
18

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
671
17

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
Yasuhiro Oki, Mansoor Noorani, Pei Lin, Richard E Davis, Sattva S Neelapu, Long Ma, Mohamed Ahmed, Maria Alma Rodriguez, Fredrick B Hagemeister, Nathan Fowler,[...]. Br J Haematol 2014
234
17

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh,[...]. J Clin Oncol 2019
193
17

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
George W Wright, Da Wei Huang, James D Phelan, Zana A Coulibaly, Sandrine Roulland, Ryan M Young, James Q Wang, Roland Schmitz, Ryan D Morin, Jeffrey Tang,[...]. Cancer Cell 2020
199
17

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
Nathalie A Johnson, Kerry J Savage, Olga Ludkovski, Susana Ben-Neriah, Ryan Woods, Christian Steidl, Martin J S Dyer, Reiner Siebert, John Kuruvilla, Richard Klasa,[...]. Blood 2009
419
16

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, Jorge J Castillo, Saurabh Rajguru, David T Yang, Khushboo A Shah, Jeremy D Whyman, Frederick Lansigan, Francisco J Hernandez-Ilizaliturri,[...]. Blood 2014
286
16

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Umberto Vitolo, Marek Trněný, David Belada, John M Burke, Angelo Michele Carella, Neil Chua, Pau Abrisqueta, Judit Demeter, Ian Flinn, Xiaonan Hong,[...]. J Clin Oncol 2017
226
16

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
William W L Choi, Dennis D Weisenburger, Timothy C Greiner, Miguel A Piris, Alison H Banham, Jan Delabie, Rita M Braziel, Huimin Geng, Javeed Iqbal, Georg Lenz,[...]. Clin Cancer Res 2009
466
15

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Zheng Zhou, Laurie H Sehn, Alfred W Rademaker, Leo I Gordon, Ann S Lacasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D Zelenetz, Gregory A Abel, Maria A Rodriguez,[...]. Blood 2014
489
15

MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Christiane Copie-Bergman, Peggy Cuillière-Dartigues, Maryse Baia, Josette Briere, Richard Delarue, Danielle Canioni, Gilles Salles, Marie Parrens, Karim Belhadj, Bettina Fabiani,[...]. Blood 2015
146
14

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.
Marita Ziepert, Dirk Hasenclever, Evelyn Kuhnt, Bertram Glass, Norbert Schmitz, Michael Pfreundschuh, Markus Loeffler. J Clin Oncol 2010
380
14

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Alex F Herrera, Matthew Mei, Lawrence Low, Haesook T Kim, Gabriel K Griffin, Joo Y Song, Reid W Merryman, Victoria Bedell, Christine Pak, Heather Sun,[...]. J Clin Oncol 2017
106
13

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
George Wright, Bruce Tan, Andreas Rosenwald, Elaine H Hurt, Adrian Wiestner, Louis M Staudt. Proc Natl Acad Sci U S A 2003
716
13

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Kerry J Savage, Nathalie A Johnson, Susana Ben-Neriah, Joseph M Connors, Laurie H Sehn, Pedro Farinha, Douglas E Horsman, Randy D Gascoyne. Blood 2009
452
13

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Sharon Barrans, Simon Crouch, Alex Smith, Kathryn Turner, Roger Owen, Russell Patmore, Eve Roman, Andrew Jack. J Clin Oncol 2010
408
13

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
13

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
969
13

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Grzegorz S Nowakowski, Betsy LaPlant, William R Macon, Craig B Reeder, James M Foran, Garth D Nelson, Carrie A Thompson, Candido E Rivera, David J Inwards, Ivana N Micallef,[...]. J Clin Oncol 2015
266
12

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
David W Scott, Rebecca L King, Annette M Staiger, Susana Ben-Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W Slack, Daisuke Ennishi,[...]. Blood 2018
98
12

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Georg Lenz, George W Wright, N C Tolga Emre, Holger Kohlhammer, Sandeep S Dave, R Eric Davis, Shannon Carty, Lloyd T Lam, A L Shaffer, Wenming Xiao,[...]. Proc Natl Acad Sci U S A 2008
679
12

Analysis of the coding genome of diffuse large B-cell lymphoma.
Laura Pasqualucci, Vladimir Trifonov, Giulia Fabbri, Jing Ma, Davide Rossi, Annalisa Chiarenza, Victoria A Wells, Adina Grunn, Monica Messina, Oliver Elliot,[...]. Nat Genet 2011
706
12

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
12

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Andrew Davies, Thomas E Cummin, Sharon Barrans, Tom Maishman, Christoph Mamot, Urban Novak, Josh Caddy, Louise Stanton, Shamim Kazmi-Stokes, Andrew McMillan,[...]. Lancet Oncol 2019
94
12

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
Andreas Rosenwald, Susanne Bens, Ranjana Advani, Sharon Barrans, Christiane Copie-Bergman, Mad-Helenie Elsensohn, Yaso Natkunam, Maria Calaminici, Birgitta Sander, Maryse Baia,[...]. J Clin Oncol 2019
78
15

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
11

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.
Daisuke Ennishi, Anja Mottok, Susana Ben-Neriah, Hennady P Shulha, Pedro Farinha, Fong Chun Chan, Barbara Meissner, Merrill Boyle, Christoffer Hother, Robert Kridel,[...]. Blood 2017
78
14

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
David Cunningham, Eliza A Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M Ardeshna, John A Radford, Andrew McMillan,[...]. Lancet 2013
330
11

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, Rudolf Schmits, Martin Mohren, Eva Lengfelder, Marcel Reiser, Christina Nickenig, Michael Clemens, Norma Peter,[...]. Lancet Oncol 2008
772
11

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
895
11

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.